Results 91 to 100 of about 399,367 (396)

Key environmental stress biomarker candidates for the optimisation of chemotherapy treatment of leukaemia [PDF]

, 2014
The impact of fluctuations of environmental parameters such as oxygen and starvation on the evolution of leukaemia is analysed in the current review.
Brito Dos Santos, Susana, Fuentes-Garí, Maria, Mantalaris, Athanasios, Misener, Ruth, Panoskaltsis, Nicki, Pefani, Eleni, Pistikopoulos, Efstratios N., Velliou, Eirini G.   +7 more
core   +1 more source

Long‐term follow‐up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic‐phase chronic myeloid leukemia

Cancer, 2019
Dasatinib, a potent Bcr‐Abl tyrosine kinase inhibitor, is approved for the treatment of chronic‐phase chronic myeloid leukemia (CML‐CP) in the frontline and salvage settings. Notable side effects include pleural effusions and myelosuppression.
K. Naqvi, E. Jabbour, Jeffrey Skinner, K. Anderson, S. Dellasala, M. Yilmaz, A. Ferrajoli, P. Bose, P. Thompson, Y. Alvarado, N. Jain, Koichi Takahashi, J. Burger, Z. Estrov, G. Borthakur, N. Pemmaraju, Shilpa Paul, J. Cortes, H. Kantarjian   +18 more
semanticscholar   +1 more source

The Regulation of Trace Metal Elements in Cancer Ferroptosis

Advanced Biology, EarlyView.
The induction of ferroptosis inhibits tumor growth, enhances anticancer efficacy, and overcomes drug resistance. Recent evidence shows nonferrous metal elements play a role in ferroptosis. This review focuses on how trace metals regulate ferroptosis processes like iron accumulation, lipid peroxidation, and antioxidant defense.
Xiaoyan Wang, Yuanyuan Xue, Lei Chang, Xuena Zhu, Wenjun Liu, Tingbo Liang   +5 more
wiley   +1 more source

Detection of BCR-ABL kinase domain mutations in CD34+ cells from newly diagnosed chronic phase CML patients and their association with imatinib resistance [PDF]

, 2011
BCR-ABL kinase domain (KD) mutations, the most common cause of imatinib resistance, are infrequently detected in newly diagnosed chronic-phase chronic myeloid leukemia (CP-CML) patients.
Aamer Aleem, Abdul Qayyum, Abid Jamil, Abid Taj, Ahmad Khalid, Ammara Tahir, Ijaz Shah, Mahwish Khan, Mubashar Naqvi, Mudassar Iqbal, Muhammad Abbad, Muhammad Ferhan, Muhammad Khalid, Najeeb ur-Rehman, Riaz ul-Haq, Shahid Baig, Tanveer Akhtar, Tariq Gill, Weng Qin, Zafar Iqbal   +19 more
core   +1 more source

Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial

Journal of Clinical Oncology, 2017
Purpose Bosutinib is a potent dual SRC/ABL kinase inhibitor approved for adults with Philadelphia chromosome–positive chronic myeloid leukemia (CML) resistant and /or intolerant to prior therapy.
J. Cortes, C. Gambacorti-Passerini, M. Deininger, M. Mauro, C. Chuah, Dong-Wook Kim, I. Dyagil, N. Glushko, D. Milojkovic, P. le Coutre, V. García‐Gutiérrez, Laurence Reilly, A. Jeynes-Ellis, E. Leip, N. Bardy-Bouxin, A. Hochhaus, T. Brümmendorf   +16 more
semanticscholar   +1 more source

Strategies to Design and Optimize Artificial Antigen‐Presenting Cells for T Cell Expansion in Cancer Immunotherapy

Advanced Functional Materials, EarlyView.
This review highlights recent advances in engineering artificial antigen‐presenting cells (aAPCs) as alternatives to dendritic cells for T cell expansion. Key design principles inspired by the immunological synapse are discussed, with emphasis on strategies for polyclonal and antigen‐specific T cell expansion.
Nguyen Thi Nguyen, Yu Seok Youn
wiley   +1 more source

Targeting quiescent leukemic stem cells using second generation autophagy inhibitors [PDF]

, 2019
In chronic myeloid leukemia (CML), tyrosine kinase inhibitor (TKI) treatment induces autophagy that promotes survival and TKI-resistance in leukemic stem cells (LSCs).
A Hamilton, A Kuma, AS Corbin, B Ronan, B Zhang, B Zhang, BJ Druker, C Bellodi, D Mahalingam, DJ Klionsky, DT Vogl, E Weisberg, F Liu, G Karsli-Uzunbas, JD Mancias, JY Guo, JY Guo, M Karvela, M Komatsu, M Mortensen, M Schemionek, MR Rosenfeld, MR Warr, MT Rosenfeldt, N Mizushima, P Rousselot, Q McAfee, R Bago, R Rangwala, R Rangwala, S Brenner, S Kimura, S Koschmieder, SM Graham, T Holyoake, TL Holyoake, TL Holyoake, TT Ho, V Kirkin, VW Rebecca, WE Dowdle, XH Ma, Z Tothova   +42 more
core   +2 more sources

Low expression of miR-196b enhances the expression of BCR-ABL1 and HOXA9 oncogenes in chronic myeloid leukemogenesis. [PDF]

PLoS ONE, 2013
MicroRNAs (miRNAs) can function as tumor suppressors or oncogene promoters during tumor development. In this study, low levels of expression of miR-196b were detected in patients with chronic myeloid leukemia.
Yue Liu, Wenling Zheng, Yanbin Song, Wenli Ma, Hong Yin   +4 more
doaj   +1 more source

Biomaterial Strategies for Targeted Intracellular Delivery to Phagocytes

Advanced Functional Materials, EarlyView.
Phagocytes are essential to a functional immune system, and their behavior defines disease outcomes. Engineered particles offer a strategic opportunity to target phagocytes, harnessing inflammatory modulation in disease. By tuning features like size, shape, and surface, these systems can modulate immune responses and improve targeted treatment for a ...
Kaitlyn E. Woodworth, Neal I. Callaghan, Locke Davenport Huyer   +2 more
wiley   +1 more source

Recent Applications of Mesoporous Silica Nanoparticles in Gene Therapy

Advanced Healthcare Materials, EarlyView.
The review summarizes the synthesis of mesoporous silica nanoparticles (MSNs) with modifiable surface properties, functionalization strategies, mechanism of therapeutic payload release, and current applications in gene therapy, focusing on their capabilities in the targeted delivery of therapeutic nucleic acids, CRISPR‐Cas systems, and other genetic ...
Tamanna Binte Huq, Punnya Anil Kumar Jeeja, Sudip Kumar Dam, Sabya Sachi Das, Juan L. Vivero‐Escoto   +4 more
wiley   +1 more source